SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis International AG Says Glivec Has Potential to Treat PAH; Drug Did Not Reach Statistical Significance In Main Target

October 8, 2008 | 
1 min read
ZURICH, Oct 8 (Reuters) - Novartis AG's cancer drug Glivec had the potential to treat a rare heart and lung condition in a mid-stage trial, but did not reach its main target in the study.
Clinical research Postmarket research Europe
MORE ON THIS TOPIC
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Immunology and inflammation
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
Regulatory
Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication
June 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of businessman with flag looking victorious on top of teetering blocks
Rare diseases
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit
June 29, 2026
 · 
2 min read
 · 
Tristan Manalac
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac